Interim Results

RNS Number : 2170V
Ilika plc
10 January 2013
 



10 January 2013

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Interim Results for the Six Months Ended 31 October 2012

 

Ilika (AIM: IKA), the advanced cleantech materials discovery company, announces its unaudited interim results for the six months ended 31 October 2012, a period which witnessed continued progress with new partnerships, contract renewals and increased business development activity in the US and Asia.

 

Ilika accelerates the discovery of new and patentable materials using its unique high throughput technologies process for identified end uses across the energy, electronics and biomedical sectors.

 

Operational Highlights

·     Granted key Patent from the US Patent and Trademark Office further protecting the Company's high-throughput technology

·     Phase 1 development of Ilika's solid state battery technology for man-portable operations (DUBS) well underway

·     Received an equity investment of £149,380 from the Carbon Trust Fund to aid commercialisation of the Company's proprietary low cost fuel cell catalyst material

·     Awarded 'University Spin-Out of the Year' at the New Energy Awards

 

Post Period End Events

·     Energizer announced a $200m cost saving programme affecting its partners including Ilika

·     Renewal of contract with world leading motor manufacturer

·     Disposal of non-core wound care business completed

·     Grant of fuel cell catalyst patent in the US

 

Financial Summary

 

Total revenue for the period was £0.5m, consisting of £0.4m from continuing activities and £0.1m from the discontinued wound care business. Whilst this is lower than the £0.8m revenue for the prior comparative period the Company expects the current strength of the business development pipeline to allow it to recognise significantly increased revenues in the second half.

 

The successful disposal of the Altrika business has resulted in an on-going overhead saving of around £0.4m per annum. Research and development expenditure in Ilika's DUBS technology has increased the first half loss to £2m, but this investment has significantly strengthened its proprietary IP position.

 

Cash balance at the period end remains strong at £3.6m.

 

Commenting on the results Ilika's Chairman, Jack Boyer, said: "The first half of 2012 witnessed several significant milestones in the development of Ilika. Firstly, the granting of the US Patent on our materials discovery technology confirmed the uniqueness of our approach. Secondly, the Carbon Trust's investment in our fuel cell technology has provided a strong springboard for the commercialisation of our low cost fuel cell catalyst. Thirdly, our team has made a determined start to phase one of Ilika's solid state battery technology for man-portable applications.

 

While we were obviously disappointed with the news that Energizer's $200m global cost saving plan affecting a number of development partners included us, it is important to understand that this relationship was only one out of twenty of our customer relationships and the technology concerned was unrelated to any of our other programmes.

 

"Post the successfully completed disposal of the non-core wound care division, we expect revenue from the continuing business to be significantly stronger in the second half of the current financial year than the first. Over the longer term, the value of our business development pipeline continues to expand providing further confidence in the development of the Company. We remain committed to investing Ilika's cash prudently to drive the Company towards profitability, whilst also completing the man-portable battery programme to deliver our shareholders attractive returns on their investment."

 

 

For more information contact:

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0) 23 8011 1400

 

 

Numis Securities Limited

Oliver Cardigan/ James Black

 

 

Walbrook PR Ltd

+44 (0) 20 7933 8780

Paul McManus (Media Enquiries)

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Enquiries)

Mob: 07827 879 460 or paul.cornelius@walbrookir.com

 



Joint Chairman's and CEO's Statement

Review of Period

 

Reinforcement of Platform Technology IP Position

In May 2012, the US Patent and Trademark Office granted Ilika a patent to protect its proprietary high throughput method for producing materials. This is a key patent, affording protection to Ilika's technology platform and recognising the novelty and uniqueness of its innovation capabilities.

 

Distributed Universal Battery System for Man-Portable Applications

At the end of the previous reporting period in April 2012, Ilika successfully secured £4.9 million of equity investment, 60 per cent of which came from new shareholders, to support the development of its solid-state battery technology for man-portable applications.

 

Ilika refers to this technology as its DUBS (Distributed Universal Battery System) programme. The concept is that the battery system is made of a number of lightweight cells, which can be distributed and connected to form a conformal power source, which is easily carried. The design has been reviewed and supported by expert groups within the US and UK defence sectors. Having secured demand from this early adoption market, Ilika intends to make this technology available to some of the higher-volume applications including consumer electronics.

 

The development of DUBS technology is structured in three phases over a period of 24 months. Phase 1 started at the beginning of this reporting period, in May 2012; and is focused on optimising the cell design. The cells are made up of a series of individual layers of materials, each of which needs to be well understood in order for the composite cell to have the required electrochemical properties. These individual layers have now been optimised and the focus of efforts in Phase 1 is combining these layers in a way that minimises the impact of the interfaces and allows the cell to function optimally. In parallel, discussions have been held with fabricators of materials deposition technology to assess their suitability for cell production.

 

Automotive Thin Film Battery Technology

The DUBS programme is an extension of the technology originally developed with Toyota for the creation of safer, lighter batteries with the ability to be rapidly charged and discharged in hybrid vehicles. Toyota remains Ilika's most important customer and continues to work closely together with Ilika in the development of battery materials, having, in December 2012, extended their contractual arrangement through seven successive renewals over five years.

 

Low-Cost Fuel Cell Catalyst

In addition to this strong progress with battery materials, Ilika has also made progress with its low-cost fuel cell technology. In September 2012, Ilika received an equity investment of £149,380 from the Carbon Trust, through its Polymer Fuel Cells Challenge programme, to support the commercialisation of Ilika's proprietary high performing electro-catalysts for use in fuel cell vehicles. In a fuel cell, a controlled reaction between hydrogen and oxygen occurs. This reaction requires electro-catalysts, which are currently based on the precious metal, platinum. Ilika has developed a novel platinum-free catalyst which, on a cost/performance basis, promises to be 70 percent cheaper than the current industry standard. As part of the Carbon Trust's technical and commercial evaluation of the technology, Ilika submitted performance data for assessment by independent experts demonstrating the performance and stability of the catalyst. The performance data was generated in industry standard tests of membrane electrode assemblies (MEA's) carried out at an independent fuel cell testing facility. The electro-catalysts have been subsequently manufactured to Ilika's specification by a partner using an industrially-scalable process. The investment from the Carbon Trust is intended to support Ilika in providing a larger quantity of the electro-catalyst for testing by the major automotive OEMs that have expressed their interest in the technology. Ilika has recently made data and initial samples available to one of its preferred automotive partners, who has commenced activities to reproduce the technical results in its own laboratories.

In December 2012, Ilika received notification that its patent application covering the use of lower cost metal alloys as electro-catalysts in PEM fuel cells has been granted in the USA.

Energizer relationship

In November 2012 Energizer, which is one of Ilika's 20 blue-chip commercial partners, announced that it had undergone a strategic review of its business and is implementing a $200 million enterprise wide, multi-year cost saving programme. Shortly after that announcement, Ilika was informed that the product development, on which it had been collaborating, was not being extended. While in the context of Ilika's balanced portfolio of commercial relationships this will not have a long-term impact, it will have a material impact on its near-term revenues for the remainder of the current financial year. In the wake of this news, Ilika's business development team has redoubled its efforts to identify new partners to commercialise Ilika's expertise in this area and drive revenue growth back to the levels it has previously enjoyed.

 

Disposal of the Wound Care Division

In the course of this reporting period, Ilika took the decision to streamline its operations by discontinuing provision of its wound care products through its wholly-owned subsidiary, Altrika, by the end of December 2012. This will allow Ilika to focus on its core activities in developing energy conversion and storage materials. The streamlining involved the disposal of Altrika Limited on 17 December 2012 and its facilities in Sheffield. As part of this rationalisation, the high throughput polymer platform was, before this disposal, transferred to Ilika Technologies Limited and has been relocated to Southampton and sited in Ilika's expanded laboratory facilities there. The transaction has a small net positive effect on Ilika's balance sheet.

 

Industry Awards

Ilika also enjoyed public recognition of its success in April 2012 when it fought off strong competition in its category to win Spin-Out of the Year at the New Energy Awards held at the Science Museum in London.

 

Outlook

Ilika generally has a stronger second half to its financial year due to the importance of Ilika's Japanese customers, who tend to award contracts at the end and beginning of their budget years, which are typically aligned with the calendar year. The second half of this financial year also promises further progress in scaling up and commercialising its low-cost fuel cell catalyst. Ilika's management looks forward to updating the market as feedback is received from its OEM partners.

 

Based on this seasonality and the current strength of its business development pipeline, Ilika is looking forward to renewed turnover growth in the second half of the current financial period with revenue from continuing operations for the full year to 30 April 2013 expected to be approximately 10 percent below that achieved in the prior financial year, as previously announced.

 

In readiness for the increased activity during the second half and beyond, Ilika has commenced an expansion of its facilities in Southampton, which will approximately double available laboratory space. This will create room for increased materials characterisation capability and also for the pilot line for its solid-state battery programme.

 

Finally, the management team remains committed to deploying Ilika's cash prudently to drive the Company towards profitability and beyond, while also delivering its DUBS programme to deliver both its long-standing and new shareholders  attractive returns on their investment.

 

Graeme Purdy, CEO

Jack Boyer, Chairman

 



Ilika plc

 

 

Consolidated statement of comprehensive income for the six months ended 31 October 2012

 



Unaudited Six months ended

31 Oct 2012

Unaudited Six months ended

31 Oct 2011

 

Audited Year

ended

30 Apr 2012


Notes

£

£

£

Continuing operations





Revenue


391,801 

745,124 

1,851,172 

Cost of sales


(296,745)

(552,160)

(1,037,908)






Gross profit


95,056 

192,964 

813,264 






Administrative expenses


(2,001,487)

(1,687,631)

(3,367,519)






Other operating income


118 

97,953 

172,097 






Operating loss


(1,906,313)

(1,396,714)

(2,382,158)






Financial income


40,533 

14,108 

16,251 

Financial expense


(2,270)

(5,486)

(10,684)






Loss before tax


(1,868,050)

(1,388,092)

(2,376,591)

Taxation


108,884 

52,955 

93,198 






Loss for period on continuing

Activities


(1,759,166)

(1,335,137)

(2,283,393)

Loss for the period on discontinued activities

3

(210,524)

(160,151)

(426,892)






Loss and total comprehensive

income and expense for the period


(1,969,690)

(1,495,288)

(2,710,285)






Loss per share

2




Basic


(0.04)

(0.04)

(0.07)

Diluted


(0.04)

(0.04)

(0.07)






Continuing operations


(0.04)

(0.04)

(0.06)

Discontinued operations


(0.00)

(0.00)

(0.01)

 



Consolidated balance sheet as at 31 October 2012

 



Unaudited

Six months ended

31 Oct 2012

Unaudited

Six months ended

31 Oct 2011

Audited

Year

ended

30 Apr 2012


Notes

£

£

£

ASSETS





Non current assets





Intangible assets


55,550 

69,927 

61,863 

Property, plant and equipment


1,110,279 

1,691,443 

1,380,257 






Total non current assets


1,165,829 

1,761,370 

1,442,120 






Current assets





Inventory


34,135 

34,135 

Trade and other receivables


555,889 

1,032,077 

660,943 

Current tax receivable


109,449 

68,378 

125,470 

Other financial assets - bank deposits


3,460,664 

701,233 

4,000,000 

Cash and cash equivalents


90,714 

504,832 

1,299,072 

Assets classified as held for sale

3

70,447 






Total current assets


4,287,163 

2,340,655 

6,119,620 






Total assets


5,452,992 

4,102,025 

7,561,740 











EQUITY





Issued share capital


475,354 

383,548 

472,638 

Share premium


8,823,770 

4,169,909 

8,677,106 

Capital restructuring reserve


6,486,077 

6,486,077 

6,486,077 

Retained earnings


(10,838,139)

(7,803,908)

(8,916,868)






Total equity


4,947,062 

3,235,626 

6,718,953 











LIABILITIES





Current liabilities





Trade and other payables


505,137 

847,538 

835,243

Liabilities classified as held for sale

3

793 






Non current liabilities





Other payables


-  

18,861 

7,544






Total liabilities


505,930 

866,399 

842,787






Total equity and liabilities


5,452,992 

4,102,025 

7,561,740

 

 

 

 

 



Consolidated cash flow statement for the six months ended 31 October 2012

 


Unaudited

Six months ended

31 Oct 2012

Unaudited

Six months ended

31 Oct 2011

Audited

Year

ended

30 Apr 2012


£

£

£

Cash flows from operating activities




Loss for period on continuing activities

(1,759,166)

(1,335,137)

(2,283,393)

Loss for the period on discontinued activities

(210,524)

(160,151)

(426,892)

Adjustments for:




Taxation

(108,884)

(68,378)

(125,470)

Amortisation

6,313 

8,632 

14,196 

Depreciation*

386,777 

415,404 

819,101 

Equity settled share based payments

48,419 

109,576 

211,613 

Loss on disposal of plant, property and

equipment

 

 

-  

 

69 

Loss on disposal of intangible assets

-  

3,582 

Net financial income

(38,263)

(8,622)

(5,567)

Operating cash flow before changes in working capital, interest and taxes

(1,675,328)

(1,038,676)

(1,792,491)

 

Decrease/(increase) in trade and other

receivables *

 

95,054 

 

(283,996)

 

87,138 

Decrease in trade and other payables*

(318,208)

(268,749)

(272,198)

Cash utilised by operations

(1,898,482)

(1,591,421)

(1,977,551)

 

Tax received

124,905 

122,733 

122,733 

Net cash flow from operating activities

(1,773,577)

(1,468,688)

(1,854,818)





Cash flows from investing activities




Interest received

33,189 

14,293 

16,251 

Purchase of intangible assets

(16,765)

(14,265)

Sale of property plant and equipment

-  

25 

Purchase of property, plant and equipment

(143,099)

(100,367)

(196,826)

Decrease/(Increase) in other financial assets

539,336 

798,767 

(2,500,000)

Net cash used in investing activities

429,426 

695,928 

(2,694,815)

 





Cash flows from financing activities




Proceeds from issuance of ordinary share capital

149,380 

-  

4,899,991 

Share issue costs

-  

-  

(303,703)

Capital element of finance leases

(11,317)

(20,846)

(40,823)

Interest element of finance leases

(2,270)

(5,486)

(10,684)

Net cash from financing activities

135,793 

(26,332)

4,544,781 





Net decrease in cash and cash equivalents

(1,208,358)

(799,092)

(4,852)

Cash and cash equivalents at the start of the period

1,299,072 

1,303,924 

1,303,924 

Cash and cash equivalents at the end of the period

90,714 

504,832 

1,299,072 

 

* This includes the assets and liabilities held as available for sale as per note 3

Consolidated statement of changes in equity (unaudited)

 


 

 

Share capital

Share premium account

Capital

restructuring reserve

 

Retained earnings

 

 

Total


£

£

£

£

£

As at 30 April 2011

383,548

4,169,909 

6,486,077 

(6,418,196)

4,621,338 

Share based  payment

-

-  

-  

109,576 

109,576 

Loss and total comprehensive income

 

-

 

-  

 

 - 

 

(1,495,288)

 

(1,495,288)

As at 31 October 2011

383,548

4,169,909 

6,486,077 

(7,803,908)

3,235,626 

Issue of shares

89,090

4,810,900 

-  

-  

4,899,990 

Expenses of share issue

-

(303,703)

-  

-  

(303,703)

Share based  payment

-

-  

-  

102,037 

102,037 

Loss and total

comprehensive income

 

-

 

-  

 

 - 

 

(1,214,997)

 

(1,214,997)

As at 30 April 2012

472,638

8,677,106 

6,486,077 

(8,916,868)

6,718,953 

Issue of shares

2,716

146,664 

149,380 

Share based  payment

-

-

-

48,419 

48,419 

Loss and total

comprehensive income on continuing activities

 

 

-

 

 

-

 

 

-

 

 

(1,759,166)

 

 

(1,759,166)

Loss and total

comprehensive income on discontinued activities

 

 

-

 

 

-  

 

 

 - 

 

 

(210,524)

 

 

(210,524)

As at 31 October 2012

475,354

8,823,770 

6,486,077 

(10,838,139)

4,947,062 

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Group since inception of the business.

 

Capital restructuring reserve

The capital restructuring reserve arises on the accounting for the share for share exchange.  It represents the difference between the value of the issued equity instruments of Ilika Technologies Limited immediately before the share for share exchange and the equity instruments of Ilika plc along with the shares issued to effect the share for share exchange.

 

Notes to the consolidated financial statements

 

1.      Accounting policies

 

Basis of preparation

 

The interim financial statements, which are unaudited, have been prepared on the basis of accounting policies consistent with International Financial Reporting Standards ("IFRSs") adopted by the European Union. The accounting policies are the same as applied in the Group's latest financial statements.

 

The IFRSs that will be effective in the financial statements for the year to 30 April 2013 are still subject to change and to the issue of additional interpretation(s) and therefore cannot be determined with certainty. Accordingly, the accounting policies for that annual period that are relevant to this interim financial information will be determined only when the IFRS financial statements are prepared at 30 April 2013.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting'. Accordingly, whilst the interim financial statements have been prepared in accordance with IFRS they cannot be construed as being in full compliance with IFRS

 

The financial information for the year ended 30 April 2012 does not constitute the full statutory accounts for that period. The Annual Report and Accounts for 30 April 2012 have been filed with the Registrar of Companies. The Independent Auditors' Report  on the Annual Report and Accounts for 2012 was unqualified and did not include references to any matters which the auditors drew attention by way of emphasis without qualifying their report and did not contain statements under Section 498(2) or 498(3) of the Companies Act 2006.

 

Going concern

 

The financial statements are prepared on a going concern basis which the directors believe continues to be appropriate. The Group meets its day to day working capital requirements through existing cash resources which, at 31 October 2012, amounted to £3,551,378. The directors have prepared projected cash flow information for the period ending twelve months from the date of their approval of these financial statements. On the basis of this cash flow information the directors believe that the Group will be able to continue to trade for the foreseeable future.

 

Assets and liabilities classified as held for sale

The assets and liabilities of disposal groups are classified as held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of the carrying value less costs to sell if their carrying amount is to be recovered principally through a sale transaction rather than through continuing use.



 

2.      Loss per share

 

Loss per ordinary share have been calculated using the weighted average number of shares in issue during the relevant financial periods. The weighted average number of equity shares in issue and the earnings, being loss after tax, are as follows:

 


Unaudited

Six months ended

31 Oct 2012

 

Unaudited

Six months ended

31 Oct 2011

 

Audited

Year

ended

30 Apr 2012


Number

Number

Number





Weighted average number of equity shares

47,330,257

38,354,759

38,525,718 






£

£

£





Loss, being loss after tax on continuing activities

(1,759,166)

(1,335,137)

(2,283,393)

Loss, being loss after tax on discontinued activities

(210,524)

(160,151)

(426,892)





 

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted earnings per ordinary share are identical to those used for basic earnings per share. This is because the exercise of share options and warrants would have the effect of reducing the loss per ordinary share and is therefore not dilutive under the terms of IAS 33.

 

3.      Discontinued operations

 

The results of the discontinued wound care division which have been included in the consolidated income statement were as follows:

 


Unaudited Six months ended

31 Oct 2012

Unaudited Six months ended

31 Oct 2011

Audited Year

ended

30 Apr 2012


£

£

£





Revenue

95,175 

89,508 

160,072 

Cost of sales

(55,424)

(52,361)

(149,861)





Gross profit

39,751 

37,147 

10,211 





Administrative expenses

(266,504)

(318,007)

(590,531)





Other operating income

16,229 

105,286 

121,156 





Operating loss and loss before tax

(210,524)

(175,574)

(459,164)





Taxation

15,423 

32,272 





Loss for the period on discontinued activities

(210,524)

(160,151)

(426,892)

 

 

 

The major classes of assets and liabilities comprising the operations classified as held for sale are as follows:

 


Period ended

31 October 2012


£

Plant and equipment

26,312

Inventories

34,135

Trade and other receivables

10,000

Total assets classified as held for sale

70,447



Trade and other payables

793

Total liabilities associated with assets classified as held for sale

793



Net assets of the disposal group

69,654

 

During the period, the discontinued operations absorbed £210,524 of the Group's net operating cashflows, £nil in respect of investing activities and £nil in respect of financing activities.

INDEPENDENT REVIEW REPORT TO ILIKA PLC

 

Introduction

 

We have been engaged by the company to review the condensed set of financial statements in the half-yearly financial report for the six months ended 31 October 2012 which comprises the Consolidated Statement of Comprehensive Income, the Consolidated Balance Sheet, the Consolidated Cash Flow Statement, the Consolidated Statement of Changes in Equity and the related notes.

 

We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

 

Directors' responsibilities

 

The interim report, including the financial information contained therein, is the responsibility of and has been approved by the directors.  The directors are responsible for preparing the interim report in accordance with the rules of the London Stock Exchange for companies trading securities on AIM which require that the half-yearly report be presented and prepared in a form consistent with that which will be adopted in the company's annual accounts having regard to the accounting standards applicable to such annual accounts.

 

Our responsibility

 

Our responsibility is to express to the company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review.

 

Our report has been prepared in accordance with the terms of our engagement to assist the company in meeting the requirements of the rules of the London Stock Exchange for companies trading securities on AIM and for no other purpose.  No person is entitled to rely on this report unless such a person is a person entitled to rely upon this report by virtue of and for the purpose of our terms of engagement or has been expressly authorised to do so by our prior written consent.  Save as above, we do not accept responsibility for this report to any other person or for any other purpose and we hereby expressly disclaim any and all such liability.

 

Scope of review

 

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, ''Review of Interim Financial Information Performed by the Independent Auditor of the Entity'', issued by the Auditing Practices Board for use in the United Kingdom.  A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.  A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.  Accordingly, we do not express an audit opinion.

 

Conclusion

 

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 31 October 2012 is not prepared, in all material respects, in accordance with the rules of the London Stock Exchange for companies trading securities on AIM.

 

 

BDO LLP

Chartered Accountants

Southampton, United Kingdom

10th January 2013

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

 

- Ends -

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LLFITLDIAIIV

Companies

Ilika (IKA)
UK 100

Latest directors dealings